Emails Show Allergan Asked Goldman To "Take off The Gloves" In Valeant FightMark Melin
Recently unearthed emails, letters to regulators and legal strategy documents sent by Allergan, Inc. (NYSE:AGN) executives and their consortium of paid consultants paint a picture of a company engaged in a multiple-prong attack to damage the reputation of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), sink its stock price and fight a regulatory battle.
Allergan's attempt to manipulate the stock price of Valeant Pharmaceuticals
Perhaps most interesting about the 30 some documents reviewed by ValueWalk, many marked “confidential” or “highly confidential . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat